Neoantigen Targeted Therapies Market

Neoantigen Targeted Therapies Market Overview

The global neoantigen targeted therapies market, valued at USD 661 million in 2025, is projected to reach USD 807 million in 2026 and USD 2,913 billion by 2030, with a 38% CAGR during the forecast period 2026 to 2030.

To learn more about this report, request a free sample copy

Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2018, in the US alone.  The World Health Organization has estimated the number of new cancer cases, reported across the globe, to rise by 70% over the next 20 years.  Conventional treatment options, such as chemotherapy, surgery and radiation therapy, continue to demonstrate limited efficacy in late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, have severe detrimental effects on patients’ quality of life. Amongst the targeted anti-cancer therapies, immunotherapy has emerged as a potent option, capable of eliminating tumor cells with minimal side effects. For instance, the introduction of the immune check point inhibitors (such as PD-1/PD-L1 and CTLA-4 inhibitors) enabled healthcare providers to offer long term clinical benefit to patients suffering from metastatic tumors. However, these therapies have been reported to generate variable / inconsistent immune responses across different patients and, as a result, only a fraction of patients have actually ended up benefiting from such treatments. In fact, it is estimated that close to 70% of treated patients do not respond to single-agent immune checkpoint therapy. 

Recent developments in genomic analysis and advances in bioinformatics have enabled the adoption of more personalized treatment approaches, such as neoantigen targeted therapies. Cancer neoantigens is a term used to refer to a subset of antigens encoded by tumor-specific, mutated genes, which have not previously been recognized by host’s immune system. These are considered to be potential biological targets that can be used to augment the therapeutic value of a number of cancer immunotherapies, including immune checkpoint inhibitors and cancer vaccines, having demonstrated the capability to elicit strong T-cell mediated immune response. Currently, several neoantigen-based therapies are being investigated in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab and nivolumab. In fact, multiple such initiatives by start-ups are backed by venture capital firms and other strategic investors. 

Recent Developments in Neoantigen Targeted Therapies Market

Several recent developments have taken place in the field of neoantigen targeted therapies market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In May 2026, Moderna and Merck reported five-year follow-up data from a Phase II trial of their personalized neoantigen mRNA cancer vaccine  combined with Keytruda in melanoma patients.
• In Apri 2026, Everest Medicines announced first-in-human clinical data for its personalized neoantigen mRNA vaccine EVM16.
• In April 2026, Transgene entered into a licensing agreement with NEC Biowith an aim to advance development of TG4050, an individualized neoantigen therapeutic vaccine for HPV-negative head and neck cancer.
• In March 2026, Transgene reported continued clinical progress of its individualized neoantigen vaccine TG4050, highlighting positive Phase I data showing durable disease-free survival and immune responses in head and neck cancer.

Scope of the Neoantigen Targeted Therapies Market Report

The “Neoantigen Targeted Therapies Market: Industry Trends and Global Forecasts, till 2030” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the neoantigen targeted therapies market. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in neoantigen targeted therapies market.

In addition to other elements, the market research report includes:

• A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer.
• Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
• A detailed publication analysis of close to 300 peer-reviewed, scientific articles published since 2015, highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on target disease indications, affiliated cancer immunotherapies, and analysis based on various relevant parameters, such as study type (review article, research article and meta-analysis), year of publication, and most popular journals (in terms of number of articles published in the given time period) within neoantigen targeted therapies market.
• An in-depth analysis of the various patents that have been filed / granted related to neoantigens since 2015. It includes information on key parameters, such as patent type, publication year, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio).
• An analysis of the various partnerships pertaining to neoantigen targeting therapies, which have been established since 2015, based on various parameters, such as the type of partnership, year of partnership, target disease indications, type of immunotherapy and the most active players.
• An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing neoantigen targeted therapies.

The key objective of neoantigen targeted therapies market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for neoantigen targeted therapies market during the forecast period. Based on multiple parameters, such as disease prevalence, anticipated adoption of neoantigen targeted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the forecast period, till 2030. The market report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (bone and cartilage cancer, colorectal cancer, head and neck cancer, renal carcinoma, hepatocellular carcinoma, lung cancer, gynecological cancer and others) [B] type of treatment (personalized and off-the-shelf), [C] type of immunotherapy (dendritic cell vaccine, DNA / RNA-based vaccine, protein / peptide-based vaccine and TIL-based therapy), [D] route of administration (intradermal, intravenous, subcutaneous, and others) and [E] key geographical regions (US, EU5 and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

The opinions and insights presented in this market research report were influenced by discussions conducted with multiple stakeholders in neoantigen targeted therapies market. The market report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

• Gabriel Nistor (Chief Scientific Officer, AIVITA Biomedical)
• Ella Sorani (Vice President Research and Development, BioLineRx)
• Heinz Lubenau (Chief Operating Officer and Co-Founder, VAXIMM)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD, unless otherwise specified.